LUCD

Lucid Diagnostics Inc. [LUCD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

LUCD Stock Summary

Top 10 Correlated ETFs

LUCD


Top 10 Correlated Stocks

LUCD


In the News

10:54 29 Mar 2024 LUCD

Lucid Diagnostics Inc. (LUCD) Q3 2023 Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2023 Results Conference Call November 14, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Co Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode.

09:18 29 Mar 2024 LUCD

Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum

Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced its Chairman and Chief Executive Officer, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023 at 10:00am EST in New York City.

12:38 29 Mar 2024 LUCD

Lucid Diagnostics Inc. (LUCD) Q2 2023 Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Ed Woo - Ascendiant Capital Kyle Mikson - Canaccord Mark Massaro - BTIG Mike Matson - Needham & Co. Operator Good day, and welcome to the Lucid Diagnostics Second Quarter 2023 Business Update Conference Call. [Operator Instructions] Please note, this event is being recorded.

07:39 29 Mar 2024 LUCD

Lucid Diagnostics Inc. (LUCD) Q1 2023 Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2023 Results Conference Call May 16, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Alex Vukasin - Canaccord Genuity Mike Matson - Needham Edward Woo - Ascendiant Capital Operator Welcome to the Lucid Diagnostics Business Update and First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

09:45 29 Mar 2024 LUCD

Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.

04:41 29 Mar 2024 LUCD

Lucid to cut 1,300 workers amid signs of flagging demand for its EVs

Lucid CEO Peter Rawlinson said the job cuts will hit "nearly every organization and level, including executives."

02:18 29 Mar 2024 LUCD

Lucid Diagnostics Inc. (LUCD) Q4 2022 Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q4 2022 Earnings Conference Call March 14, 2023 8:30 AM ET Company Participants Michael Parks - Vice President, Investor Relations Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Co. Mark Massaro - BTIG Edward Woo - Ascendiant Capital Operator Welcome to the Lucid Diagnostics Business Update and Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants will be in a listen-only mode.

09:50 29 Mar 2024 LUCD

Lucid Diagnostics Inc. (LUCD) Q3 2022 Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Adrian Miller - Vice President-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Ross Osborn - Cantor Fitzgerald Ed Woo - Ascendiant Capital Greetings, and welcome to Lucid Diagnostics Third Quarterly Update Conference Call and Webcast. At this time, all participants are in a listen-only mode.

08:25 29 Mar 2024 LUCD

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022

NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT.

09:57 29 Mar 2024 LUCD

Lucid Diagnostics Inc. (LUCD) CEO Lishan Aklog on Q2 2022 Results - Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Adrian Miller - Vice President-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Company Ed Woo - Ascendiant Capital Mark Massaro - BTIG Operator Greetings, and welcome to Lucid Diagnostics Second Quarter 2020 Business Update Conference Call. At this time, all participants are in a listen-only mode.

LUCD Financial details

Company Rating
Neutral
Market Cap
48.69M
Income
-2.02B
Revenue
1.5M
Book val./share
0.06
Cash/share
0.57
Dividend
-
Dividend %
-
Employees
74
Optionable
No
Shortable
Yes
Earnings
26 Mar 2024
P/E
-0.03
Forward P/E
-0.96
PEG
-0
P/S
44.07
P/B
24.24
P/C
1.42
P/FCF
-2.42
Quick Ratio
0.8
Current Ratio
0.9
Debt / Equity
6.29
LT Debt / Equity
0.18
-
-
EPS (TTM)
-49.33
EPS next Y
-0.84
EPS next Q
-0.23
EPS this Y
0.65%
EPS next Y
-98.3%
EPS next 5Y
-99.23%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
392.45%
EPS Q/Q
25.93%
-
-
-
-
SMA20
-17.46%
SMA50
-28.28%
SMA100
-19.38%
Inst Own
1.59%
Inst Trans
0.35%
ROA
-6075%
ROE
-12318%
ROC
-17.2%
Gross Margin
-309%
Oper. Margin
-3464%
Profit Margin
-134639%
Payout
-
Shs Outstand
48.24M
Shs Float
11.57M
-
-
-
-
Target Price
3.3
52W Range
0.994-1.85
52W High
-
52W Low
-
RSI
15.53
Rel Volume
10.16
Avg Volume
97.66K
Volume
991.74K
Perf Week
-25.01%
Perf Month
-39.56%
Perf Quarter
-35.21%
Perf Half Y
-45.28%
-
-
-
-
Beta
1.73
-
-
Volatility
0.1%, 0.12%
Prev Close
-18.19%
Price
0.8099
Change
-18.19%

LUCD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
000.030.01
Net income per share
-0.12-0.22-1.54-1.55
Operating cash flow per share
-0.06-0.15-0.95-0.82
Free cash flow per share
-0.06-0.15-1-0.85
Cash per share
0.010.012.940.66
Book value per share
-0.14-0.372.940.64
Tangible book value per share
-0.14-0.372.940.54
Share holders equity per share
-0.14-0.372.940.64
Interest debt per share
000.040.06
Market cap
435.03M435.03M99.9M49.19M
Enterprise value
434.87M434.92M46.25M28.72M
P/E ratio
-98.41-52.54-3.48-0.88
Price to sales ratio
00199.8130.49
POCF ratio
-184.22-77.29-5.65-1.66
PFCF ratio
-184.22-77.29-5.39-1.61
P/B Ratio
-81.94-32.181.832.13
PTB ratio
-81.94-32.181.832.13
EV to sales
0092.4976.18
Enterprise value over EBITDA
-98.37-52.53-1.69-0.53
EV to operating cash flow
-184.16-77.27-2.62-0.97
EV to free cash flow
-184.16-77.27-2.5-0.94
Earnings yield
-0.01-0.02-0.29-1.14
Free cash flow yield
-0.01-0.01-0.19-0.62
Debt to equity
0000.09
Debt to assets
0000.06
Net debt to EBITDA
0.040.011.960.38
Current ratio
0.060.0913.452.89
Interest coverage
00-41.610
Income quality
0.530.680.630.53
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0025.5662.82
Research and developement to revenue
0018.5930.41
Intangibles to total assets
0000.11
Capex to operating cash flow
000.050.03
Capex to revenue
00-1.72-2.41
Capex to depreciation
00-215.5-0.47
Stock based compensation to revenue
0019.239.76
Graham number
0.621.3610.114.72
ROIC
00-0.51-2.08
Return on tangible assets
-4.28-3.77-0.49-1.93
Graham Net
-0.16-0.412.740.4
Working capital
-5.95M-14.27M53.04M15.93M
Tangible asset value
-5.31M-13.52M54.74M19.6M
Net current asset value
-5.95M-14.27M53.04M14.89M
Invested capital
0000.09
Average receivables
00.5100K108.5K
Average payables
01.43M1.77M1.27M
Average inventory
0416.88K663.38K302K
Days sales outstanding
0014616.46
Days payables outstanding
00929.66106.65
Days of inventory on hand
00307.611.21
Receivables turnover
002.522.18
Payables turnover
000.393.42
Inventory turnover
001.1932.56
ROE
0.830.61-0.52-2.44
Capex per share
00-0.05-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.0100.02
Net income per share
-0.39-0.41-48.31-0.27-0.34
Operating cash flow per share
-0.17-0.12-0.17-0.17-0.21
Free cash flow per share
-0.18-0.12-0.17-0.17-0.21
Cash per share
0.810.661.010.840.57
Book value per share
0.760.640.610.360.06
Tangible book value per share
0.650.540.540.30.01
Share holders equity per share
0.760.640.610.360.06
Interest debt per share
0.060.050.340.330.39
Market cap
55.7M49.19M57.36M58.15M48.98M
Enterprise value
30.77M28.72M31.61M39.02M41.01M
P/E ratio
-0.97-0.83-0.01-1.28-0.86
Price to sales ratio
732.91439.24128.61365.7262.55
POCF ratio
-8.78-11.55-8.14-8.29-5.58
PFCF ratio
-8.35-11.03-8.12-8.28-5.57
P/B Ratio
2.022.132.33.8619.16
PTB ratio
2.022.132.33.8619.16
EV to sales
404.87256.4270.88245.4152.38
Enterprise value over EBITDA
-2.24-2.01-2.03-3.61-3.06
EV to operating cash flow
-4.85-6.74-4.49-5.56-4.67
EV to free cash flow
-4.62-6.44-4.48-5.55-4.66
Earnings yield
-0.26-0.3-34.51-0.2-0.29
Free cash flow yield
-0.12-0.09-0.12-0.12-0.18
Debt to equity
0.070.090.550.896.29
Debt to assets
0.050.060.280.320.48
Net debt to EBITDA
1.811.431.651.770.59
Current ratio
3.082.891.781.340.9
Interest coverage
086.29-433.85-51.95-74.68
Income quality
0.440.290.430.620.62
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
74.4748.7714.624.095.52
Research and developement to revenue
35.5821.85.1211.492.06
Intangibles to total assets
0.10.110.060.060.06
Capex to operating cash flow
0.050.05000
Capex to revenue
-4.22-1.81-0.04-0.09-0.02
Capex to depreciation
-0.54-0.33-0.03-0.02-0.02
Stock based compensation to revenue
4733.397.198.81.6
Graham number
2.592.4225.711.480.68
ROIC
-0.45-0.55-43-0.39-0.44
Return on tangible assets
-0.42-0.51-42.85-0.28-0.45
Graham Net
0.510.40.420.19-0.16
Working capital
20.15M15.93M18.33M9.07M-2.92M
Tangible asset value
23.58M19.6M21.97M12.64M627K
Net current asset value
19M14.89M17.5M8.33M-3.39M
Invested capital
0.070.090.550.896.29
Average receivables
15.5K24K22K31K28K
Average payables
1.75M1.08M840.5K631K815.5K
Average inventory
192K107.5K86.5K52K116K
Days sales outstanding
36.7113.665.4519.812.41
Days payables outstanding
6158.7442.0437.0154.75
Days of inventory on hand
5.766.174.172.4410.47
Receivables turnover
2.456.5916.524.5437.29
Payables turnover
1.481.532.142.431.64
Inventory turnover
15.6314.5821.5836.888.6
ROE
-0.52-0.64-79.47-0.76-5.56
Capex per share
-0.01-0.01000

LUCD Frequently Asked Questions

What is Lucid Diagnostics Inc. stock symbol ?

Lucid Diagnostics Inc. is a US stock , located in New york of Ny and trading under the symbol LUCD

Is Lucid Diagnostics Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $3.3. The lowest prediction is $3.1 and the highest is $3.5

What is LUCD stock prediction ?

What is Lucid Diagnostics Inc. stock quote today ?

Lucid Diagnostics Inc. stock price is $0.8099 today.

Is Lucid Diagnostics Inc. stock public?

Yes, Lucid Diagnostics Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap